MedPath

FDA Approves Zytiga for First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer

• The FDA has expanded the approval of Johnson & Johnson's Zytiga (abiraterone acetate) for treating metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. • This expanded indication allows physicians to prescribe Zytiga as a first-line treatment option for men diagnosed with mCRPC. • Prostate cancer remains a significant health concern, with estimates of over 28,000 deaths in the U.S. in 2012, underscoring the need for effective treatments. • Janssen Research & Development is also seeking further approvals for expanded usage of Zytiga in other countries, following a positive opinion from the European Medicines Agency.

Janssen Research & Development, a subsidiary of Johnson & Johnson, announced FDA approval for the expanded use of Zytiga (abiraterone acetate) in treating metastatic castration-resistant prostate cancer (mCRPC). This approval now allows Zytiga to be prescribed as a first-line treatment, even before chemotherapy is considered.

Significance of the Approval

Previously, Zytiga was only approved for mCRPC patients who had already undergone docetaxel-based chemotherapy. The new indication broadens the treatment landscape, providing an alternative for patients who may not be suitable candidates for chemotherapy or for whom chemotherapy has failed. This offers a significant advantage, potentially improving outcomes and quality of life for a larger population of men with mCRPC.

Prostate Cancer Burden

Prostate cancer is the most frequently diagnosed cancer in men in the U.S., excluding skin cancers. In 2012, the American Cancer Society estimated that over 28,000 men would die from the disease, making it the second leading cause of cancer death among men, behind lung cancer. Approximately 35,000 new cases of mCRPC are diagnosed each year, highlighting the urgent need for effective treatment options.

Ongoing Expansion Efforts

Janssen is actively pursuing further approvals for Zytiga's expanded usage in other regions. The company has already received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, signaling potential future availability in Europe.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Yuhan's Lung Cancer Drug Leclaza Secures European Approval in Combination Therapy

Yuhan Corporation's third-generation EGFR-TKI lazertinib (Leclaza) has received European Commission approval in combination with J&J's Rybrevant for first-line treatment of EGFR-mutated non-small cell lung cancer.
The Phase 3 MARIPOSA study demonstrated the combination therapy reduced disease progression risk by 30% compared to osimertinib, with median progression-free survival of 23.7 months versus 16.6 months.

uniQure Receives FDA Nod for Accelerated Approval Pathway for Huntington's Disease Gene Therapy

uniQure secured FDA agreement to pursue accelerated approval for its Huntington's disease gene therapy, potentially expediting treatment availability.
The FDA's decision reflects a more flexible approach to genetic medicines for severe rare diseases under Peter Marks.

FDA Approves Zymeworks' Zanidatamab (Ziihera) for HER2-Positive Biliary Tract Cancer

The FDA has approved zanidatamab (Ziihera), developed by Zymeworks, for treating HER2-positive metastatic biliary tract cancer, a rare and aggressive gastrointestinal cancer.
The approval was based on Phase 2b trial results showing a 52% objective response rate and a median duration of response of 15 months in treated patients.

FDA Grants Accelerated Approval to Jazz Pharmaceuticals' Ziihera for HER2-Positive Biliary Tract Cancer

The FDA granted accelerated approval to Jazz Pharmaceuticals’ Ziihera (zanidatamab-hrii) for HER2-positive biliary tract cancer (BTC) after prior treatment.
Ziihera, a bispecific antibody, offers a chemotherapy-free option for BTC patients, potentially improving their quality of life and overall survival rates.

Nipocalimab Granted FDA Breakthrough Therapy Designation for Sjögren's Disease

Johnson & Johnson's nipocalimab, an anti-FcRn antibody, has received FDA Breakthrough Therapy Designation for moderate-to-severe Sjögren's Disease (SjD).
The designation aims to expedite the development and review of nipocalimab, addressing a significant unmet need in SjD treatment.

Nipocalimab Granted FDA Breakthrough Therapy Designation for Sjögren’s Disease

Johnson & Johnson's nipocalimab receives Breakthrough Therapy Designation (BTD) from the FDA for moderate-to-severe Sjögren’s Disease (SjD).
The BTD is supported by positive Phase II DAHLIAS trial results, marking nipocalimab as the first FcRn blocker with such outcomes in SjD.

MHRA Approves J&J's Balversa (erdafitinib) for FGFR3-Altered Bladder Cancer

The MHRA has granted marketing authorization for Balversa (erdafitinib) as a monotherapy for adults with unresectable or metastatic urothelial carcinoma (UC).
This approval is specifically for patients with FGFR3 genetic alterations who have previously received PD-1 or PD-L1 inhibitor therapy.

J&J Seeks FDA and EMA Approval for Darzalex Faspro in High-Risk Smoldering Multiple Myeloma

Johnson & Johnson has applied to the FDA and EMA for Darzalex Faspro to treat high-risk smoldering multiple myeloma.
The application is based on Phase 3 AQUILA study data, evaluating Darzalex Faspro as a monotherapy in adults.

Johnson & Johnson Seeks FDA Approval for Subcutaneous Amivantamab in NSCLC

Johnson & Johnson has submitted a BLA to the FDA for a subcutaneous formulation of amivantamab for NSCLC treatment.
The application includes a fixed formulation of amivantamab and recombinant human hyaluronidase for SC administration.

FDA Approves AstraZeneca and Ionis' Wainua for Hereditary ATTR Polyneuropathy

The FDA has approved AstraZeneca and Ionis' Wainua (eplontersen) for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Approval was based on the NEURO-TTRansform study, demonstrating Wainua's ability to improve neuropathy impairment and quality of life.

Reference News

[1]
FDA Permits Using Johnson & Johnson Cancer Drug Without Chemo
aol.com · Dec 1, 2024

FDA approves Janssen's Zytiga for mCRPC without prior chemo; European Medicines Agency also gives positive opinion. John...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy